Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

  • End date
    Apr 1, 2024
  • participants needed
  • sponsor
    Northwestern University
Updated on 25 February 2022
platelet count
venous pressure
hepatocellular carcinoma
varicose veins
hepatic venous pressure gradient
gastric varices
biopsy of liver


Evaluate the safety and efficacy of Yttrium-90 (90Y) radioembolization for the management of thrombocytopenia.


This protocol will provide access to TheraSphere treatment for patients who have refractory thrombocytopenia secondary to cirrhosis. This protocol will utilize splenic artery-directed TheraSphere treatment.

Condition Thrombocytopenia, Cirrhosis
Treatment TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Clinical Study IdentifierNCT03059030
SponsorNorthwestern University
Last Modified on25 February 2022


Yes No Not Sure

Inclusion Criteria

Male or female, 18 years of age or older, of any ethnic or racial group
Diagnosis of cirrhosis or portal hypertension with a serum platelet count less than or equal to 80 109/L. [Rationale: platelet count <100 109/L triples the rate of liver-related adverse events (3) and worsens postoperative survival in the setting of hepatocellular carcinoma (HCC) (4). Initial platelet count of 80 109/L can allow the majority of patients who successfully respond to 90Y-RE (clinical endpoint of 50% platelet count increase) to exceed the 100 109/L threshold.]
Cirrhosis is defined by one of three criteria
Liver Biopsy/histology consistent with cirrhotic architectural liver changes
Portal hypertension (Hepatic venous pressure gradient 10 mm Hg)
Evidence of esophageal and/or gastric varices
Patients must have evidence of splenomegaly as determined by screening cross-sectional imaging
No evidence of myelosuppression (e.g. lymphopenia) as evidenced by normal hematology values at Screening
Adequate baseline organ function(with the exception of cirrhosis) as evidenced by normal BUN/Cr and electrolytes on screening chemistry
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2
Patient has a life expectancy of greater than 6 months without intervention
Patient is willing to participate in the study and has signed the study informed consent
Women of childbearing potential must have a negative serum pregnancy test within 28 days prior to screening and must not be breastfeeding

Exclusion Criteria

Patients with serum platelet count less than 10 109/L
History of bleeding disorder attributed to another cause other than cirrhosis (e.g. Von Willebrand disease)
Declines or unable to provide informed consent
History of prior partial splenic embolization (PSE) or splenectomy
Use of any medication known to increase platelet count 1 month prior to Baseline
History of allergy or sensitivity to TheraSphere or its components
History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
Contraindications to angiography and selective visceral catheterization such as bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)
Previous randomization in a trial using 90Y RE
Patient must not have participated or enrolled in a clinical trial with an investigational device / therapy within 30 days prior to randomization
Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, cardiac arrhythmias, and uncontrolled congestive heart failure or respiratory disease
Patients actively on chemotherapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note